on OXURION (EBR:OXUR)
Oxurion strengthens its clinical research platform with a new biometric partnership
Oxurion NV, a Belgian biopharmaceutical company, has announced a strategic partnership between its subsidiary Axiodis CRO and KYomed INNOV & CEISO, a French CRO. This partnership aims to strengthen Oxurion's clinical research platform with specialized biometric services. Axiodis CRO will handle clinical data management, biostatistics, and other essential biometric aspects for various development projects led by KYomed INNOV & CEISO.
The partnership addresses a growing demand for biometric services in clinical development. Oxurion estimates that this collaboration will generate between €110,000 and €170,000 in revenue annually. This initiative supports Oxurion's strategy of creating an integrated platform combining scientific services, digital technologies, and specialized expertise.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news